03.02.2019 • NewsElaine BurridgeGevo

Gevo Develops Renewable Isoprene from Waste Alcohols

Gevo Develops Renewable Isoprene from Waste Alcohols (c) Gevo
Gevo Develops Renewable Isoprene from Waste Alcohols (c) Gevo

US clean technology company Gevo has developed a catalytic process that converts waste alcohols into renewable isoprene. The company Gevo expects the isoprene produced by its proprietary process will be able to compete head-to-head on price with natural and petroleum-based chemical equivalents, while also reducing CO2 emissions.

“Renewable, low-carbon, low-cost isoprene has been pursued by a lot of companies over the years without commercial success. This is the first time in my 30 years in this industry where I have seen what I believe to be a viable route to fully renewable, low-cost isoprene,” said Gevo CEO Patrick Gruber. “I look forward to seeing this one get commercially developed. It looks as if this technology could address a large current unmet need in the marketplace and make money.”

The technology transforms low-value fusel oils – mixtures of several alcohols produced as by-products from fermentation processes such as ethanol production – into renewable isoprene. According to Gevo, fusel oils from the ethanol industry alone equate to about 2.5 million t of potential bio-based waste feedstock.

Gruber said Gevo expects to license the technology, noting that potential licensees could be ethanol producers that want to improve the profitability of their facilities, chemical plants that want cost-competitive low-carbon isoprene, or even standalone businesses.

Isoprene is used primarily to make synthetic rubber. The market for isoprene is estimated to expand at a compound annual growth rate of 7% or more to reach a value of around $4 billion by 2025, Gevo said, driven by growth in the automotive sector.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.